Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

NCT05403333 | Unknown Phase 2

• 1 other identifier: DOUBLE
• Study Type: interventional
• Target: 61
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a phase II trial to explore the efficacy and safety of weekly utidelone in HER2-negative inoperable locally advanced or metastatic breast cancer.

Conditions

Breast Neoplasms; Locally Advanced or Metastatic Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Progression free survival (PFS)

  PFS is defined as the duration from enrollment to the first radiologically confirmed progressive disease (PD) (RECIST 1.1 criteria) or death due to any cause.

  Estimated 12 months

Secondary Outcomes (4)

• Objective response rate (ORR)

  Estimated 12 months

• Overall Survival (OS)

  Estimated 24 months

• Duration of Response (DOR)

  Estimated 12 months

• Overall summary of adverse events following intravenous administration of utidelone (safety analysis set)

  Estimated 12 months

Study Arms (1)

Utidelone

EXPERIMENTAL

Drug: utidelone Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days

Drug: utidelone

Interventions

utidelone DRUG

Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days

Also known as: Singel arm

Utidelone

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed Informed Consent Form;
• Women aged ≥ 18 years;
• Histologically or cytologically confirmed HER2-negative locally advanced or metastatic breast cancer:
• The most recent pathology confirmed HER2 negative, defined as HER2 0/1 + by standard immunohistochemical staining (IHC) or HER2 2 + by IHC but negative by in situ hybridization (ISH);
• Patients with locally advanced or locally recurrent disease should be unable to undergo radical surgical resection confirmed by the investigators;
• Eastern Cooperative Oncology Group (ECOG) score \[0-2\] points;
• At least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST1.1):
• If there is only bone metastasis, it is required that the bone metastasis lesion contains bone destruction component;
• if there is only pleural effusion, it is required that the pleural effusion is malignant confirmed by pathology
• No more than 2 prior lines of chemotherapy for advanced and/or metastatic disease;
• Prior chemotherapy regimens must have included taxane;
• Patients with hormone receptor positive disease received at least one line of endocrine therapy for metastatic disease (including CDK4/6 inhibitors, everolimus, chidamide and PI3K inhibitors, etc.);
• Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior anticancer therapy. with the following exceptions: 1). alopecia; 2). pigmentation;
• Adequate hematological, hepatic and renal function;
• Life expectancy of at least 12 weeks;

You may not qualify if:

• Previous treatment with UTD-1;
• Patients with other malignant tumors within 5 years prior to enrollment, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;
• Anti-tumor therapy, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy within 4 weeks prior to the start of study treatment; endocrine therapy within 2 weeks prior to the start of study treatment;
• Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks prior to study treatment, or need to undergo elective surgery during the trial;
• Patients with clinically suspected brain metastases. However, patients who have received previous treatment for central nervous system metastasis (radiotherapy or surgery) can be included if they have been confirmed as stable by imaging for at least 4 weeks and have stopped symptomatic treatment (including hormone and mannitol, etc.) for more than 2 weeks;
• Patients with active HBV, HCV and HIV infection; except patients with stable hepatitis B after drug treatment (DNA titer should not be higher than 500 IU/mL or copy number \< 1000 copies/ml) and patients with cured hepatitis C (HCV RNA test negative);
• Peripheral neuropathy ≥grade 2 (CTCAE 5.0) and patients with grade 1 peripheral neuropathy will be enrolled at the discretion of the investigator;
• Prior grade 3 or above nervous system-related adverse events caused by previous use of anti-microtubule drugs;
• Pregnant or lactating female patients or fertile women with positive baseline pregnancy test; or subjects of childbearing potential who are unwilling to take effective contraceptive measures during the study period and within at least 90 days after the last dose;
• Known or suspected hypersensitivity to any of the study drugs or excipients;

Sponsors & Collaborators

• Fudan University: lead

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: April 18, 2022
• First Posted: June 3, 2022
• Study Start: June 10, 2022
• Primary Completion: March 9, 2023
• Study Completion: March 9, 2025
• Last Updated: June 3, 2022

Record last verified: 2022-05